Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis. (2nd October 2021)

• Record Type: Journal Article
• Authors: Akbar, Ayesha; Arnott, Ian; Kennedy, Nicholas A; Nolan, Jonathan; Peake, Simon; Whiteoak, Simon R; Probert, Chris; Fraser, Aileen; Cheshire, Alex; Lewis, Allyson; Sugrue, Kathleen; Laird, Susan; Scott, Glyn
• Is Part Of: British journal of hospital medicine. Volume 82:Number 10(2021)
• Page Start: 1
• Page End: 11
• Publication Date: 2021-10-02
• Subjects: Inflammatory bowel disease -- Mesalazine -- Ulcerative colitis; Medicine -- Periodicals; Hospital care -- Periodicals; 610.5
• DOI: 10.12968/hmed.2021.0399
• Languages: English
• ISSNs: 1750-8460

Abstract

Abstract : The 2021 National report from IBD UK included responses from over 10 000 patients with inflammatory bowel disease, over 70% of whom reported having at least one flare in the last 12 months. As the first-line treatment for patients with mild and moderate ulcerative colitis, the action and delivery mechanisms of mesalazine are crucial for successful management of the disease. The choice of the most appropriate formulation of mesalazine and securing patient concordance and adherence to treatment remains a challenge for healthcare professionals. This article details the outcome of a roundtable discussion involving a group of gastroenterology consultants and specialist nurses which considered the importance of ensuring that patients have individualised mesalazine therapy before escalation to other treatments and gives recommendations for the management of patients with mild or moderate ulcerative colitis.